Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 4/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 0.69 |
| ▸ | HTR2A | P28223 | 4/20 | 0.69 |
| ▸ | HTR2C | P28335 | 4/20 | 0.69 |
| ▸ | HTR2B | P41595 | 3/20 | 0.69 |
| ▸ | HTR1A | P08908 | 3/20 | 0.69 |
| ▸ | HPGD | P15428 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 3/20 | 0.68 |
| ▸ | GAA | P10253 | 1/20 | 0.68 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.65 |
| ▸ | AHR | P35869 | 1/20 | 0.62 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gramine SCHEMBL29351803 | 1.00 | ALDH1A1 (1.00) | ALDH1A1KMT2AMEN1KDM4ECYP3A4 | |
| Gramine SCHEMBL9058128 | 0.98 | ALDH1A1 (0.96) | ALDH1A1KMT2AMEN1KDM4ECYP3A4 | |
| Gramine SCHEMBL7434281 | 0.96 | ALDH1A1 (0.93) | ALDH1A1KMT2AMEN1KDM4ECYP3A4 | |
| Gramine SCHEMBL20906415 | 0.87 | ALDH1A1 (0.77) | ALDH1A1KMT2AMEN1KDM4ECYP3A4 | |
| Gramine SCHEMBL8704815 | 0.85 | ALDH1A1 (0.72) | ALDH1A1KMT2AMEN1KDM4ECYP3A4 | |
| SCHEMBL947574 | 0.84 | KMT2A (0.73) | ALDH1A1KMT2AMEN1KDM4ECYP3A4 | |
| SCHEMBL22619123 | 0.84 | ALDH1A1 (0.73) | ALDH1A1KMT2AMEN1KDM4ECYP3A4 | |
| N,N-Dimethyltryptamine SCHEMBL335710 | 0.81 | HTR2A (1.00) | ALDH1A1KMT2AMEN1KDM4ECYP3A4 | |
| SCHEMBL1027348 | 0.81 | ALDH1A1 (1.00) | ALDH1A1KMT2AMEN1KDM4ECYP3A4 | |
| N,N-Dimethyltryptamine SCHEMBL29350959 | 0.81 | HTR2A (1.00) | ALDH1A1KMT2AMEN1KDM4ECYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1187 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260091067-A1 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING INSULIN-ASSOCIATED DISEASES | MARVELBIOME INC (US) | 2026-04-02 | — | — | US | claimed |
| WO-2025262555-A1 | SECURE COMMUNICATION SYSTEMS AND METHODS FOR GPU ACCELERATION IN TRUSTED EXECUTION ENVIRONMENTS | MODELYO TECHNOLOGIES LTD (IL) | 2025-12-26 | — | — | WO | claimed |
| EP-4624483-A1 | GRAMINE-PLATINUM (IV) COMPLEX AS WELL AS PREPARATION METHOD THEREFOR AND ANTI-TUMOR USE THEREOF | Tianjin Medical University Cancer Institute and Hospital (CN) | 2025-10-01 | — | — | EP | claimed |
| US-20250243345-A1 | RUBBER COMPOSITION AND PNEUMATIC TIRE | TOYO TIRE CORPORATION (JP) | 2025-07-31 | — | — | US | claimed |
| US-20250243350-A1 | RUBBER COMPOSITION AND PNEUMATIC TIRE | TOYO TIRE CORPORATION (JP) | 2025-07-31 | — | — | US | claimed |
| EP-4587116-A2 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING INSULIN-ASSOCIATED DISEASES | MarvelBiome, Inc. (US) | 2025-07-23 | — | — | EP | claimed |
| WO-2025054048-A1 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING LIPID AND CHOLESTEROL METABOLISM ASSOCIATED DISEASES, DISORDERS, AND CONDITIONS | MarvelBiome, Inc. (US) | 2025-03-13 | — | — | WO | claimed |
| EP-4456723-A1 | ANTIMICROBIAL SYSTEM WITH BETA CARBOLINE ALKALOID AND INDOLE ALKALOID AND COMPOSITIONS COMPRISING THEM | Unilever IP Holdings B.V. (NL) | 2024-11-06 | — | — | EP | claimed |
| EP-4440342-A1 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING VAGUS NERVE ASSOCIATED DISEASES, DISORDERS, AND CONDITIONS | MarvelBiome, Inc. (US) | 2024-10-09 | — | — | EP | claimed |
| EP-4401745-A1 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING NEURODEGENERATIVE DISEASES | MarvelBiome, Inc. (US) | 2024-07-24 | — | — | EP | claimed |
| US-6106599-A | Inks | XEROX CORPORATION (US) | 2000-08-22 | — | — | US | claimed |
| CN-1202182-A | Curable compositions | SMITH & NEPHEW (GB) | 1998-12-16 | — | — | CN | claimed |
| EP-0850256-A1 | CURABLE COMPOSITIONS | Smith & Nephew plc (GB) | 1998-07-01 | — | — | EP | claimed |
| WO-1997010275-A1 | CURABLE COMPOSITIONS | SMITH & NEPHEW PLC (GB) | 1997-03-20 | — | — | WO | claimed |
| EP-0598022-B1 | PROCESS FOR WETTING GRAIN WITH A LIQUID AND DEVICE FOR IMPLEMENTING THE PROCESS AND THE APPLICATION OF THE PROCESS | GRAEF DIETER OTTO (DE) | 1995-05-24 | — | — | EP | claimed |
| US-5210215-A | Reacting indoles, dimethylamine and formaldehyde to gramines, condensing with malonic compounds to tryptophans, converting to 3-indolepyruvic acids; also preparation from indoles by reaction with alkyl ester oximes of 3-bromopyruvic acid | POLIFARMA S.P.A. (IT) | 1993-05-11 | — | — | US | claimed |
| EP-0421946-A2 | 3-indolepyruvic acid derivatives their method of production and therapeutic use | POLIFARMA S.p.A. (IT) | 1991-04-10 | — | — | EP | claimed |
| EP-0037271-B1 | INDOLE DERIVATIVES AND PROCESS FOR PREPARING THE SAME | TORAY INDUSTRIES, INC. (JP) | 1984-01-18 | — | — | EP | claimed |
| EP-0037271-A1 | Indole derivatives and process for preparing the same | TORAY INDUSTRIES, INC. (JP) | 1981-10-07 | — | — | EP | claimed |
| US-3997539-A | HYPOTENSIVE, TRANQUILIZER | AMERICAN HOECHST CORPORATION (US) | 1976-12-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260091067-A1 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING INSULIN-ASSOCIATED DISEASES | IAPP, GPR119, FAHD1 | ALDH1A1 1370/4885KMT2A 2945/4885MEN1 361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.